<SEC-DOCUMENT>0001144204-17-034221.txt : 20170627
<SEC-HEADER>0001144204-17-034221.hdr.sgml : 20170627
<ACCEPTANCE-DATETIME>20170627070009
ACCESSION NUMBER:		0001144204-17-034221
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170627
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170627
DATE AS OF CHANGE:		20170627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		17931124

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v469609_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K<BR>
CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>June 27, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0.5in; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company&nbsp;&#9744;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 52%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<FONT STYLE="background-color: white">&nbsp;</FONT>&nbsp;
</FONT>&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01. Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 27, 2017, Synthetic Biologics,
Inc., a Nevada corporation (the &ldquo;Company&rdquo;), issued the attached press release that included notification that the U.S.
Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application that covers the use of the active agent
of SYN-010, the Company&rsquo;s proprietary, modified-release formulation of lovastatin lactone, for the treatment of constipation.
Upon issuance, this patent will strengthen the intellectual property estate covering the use of SYN-010 for the treatment of IBS-C
until at least 2034. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 12%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid">Exhibit<BR>
        No.</P></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 85%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid">Description</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top">99.1</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Synthetic Biologics, Inc. press release dated June 27,
2017</P>
</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;&nbsp;June 27, 2017</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 42%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Steven Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v469609_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #595959">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #595959">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #595959">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Announces Allowance
of Key U.S. Patent Covering SYN-010</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intended for the Novel Treatment of Irritable
Bowel Syndrome with Constipation (IBS-C)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B><I>-- Allowance of Patent Provides
Exclusive Method of Use Protection Until at Least 2034 --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, June 27, 2017 &ndash;
</B><FONT STYLE="color: Blue"><U>Synthetic Biologics, Inc.</U></FONT> (NYSE MKT: SYN), a late-stage clinical company developing
therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent
and Trademark Office (USPTO) issued a Notice of Allowance for a patent application which covers the use of the active agent of
SYN-010, the Company&rsquo;s proprietary, modified-release formulation of lovastatin lactone, for the treatment of constipation.
Upon issuance, this patent will strengthen the intellectual property estate covering the use of SYN-010 for the treatment of IBS-C
until at least 2034, affording the Company an extended term for commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. Patent Application No. 14/776,465,
which is owned by Cedars-Sinai Medical Center (CSMC) and exclusively licensed to Synthetic Biologics, is based on innovative research
led by Mark Pimentel, M.D., FRCP(C), Program Director of CSMC&rsquo;s Medically Associated Science and Technology (MAST) Program
and Chairman of Synthetic Biologics&rsquo; IBS-C Clinical Advisory Board, which correlates methane production in the gut by certain
microorganisms (<I>M. smithii</I>) with symptoms commonly associated with IBS-C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The allowance of this new patent expands
the SYN-010 intellectual property portfolio to approximately 55 issued U.S. and foreign patents. In addition, there are approximately
25 U.S. and foreign patents pending, which upon issuance should further strengthen the intellectual property position surrounding
SYN-010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Once issued, this patent will extend
the protection around the use of SYN-010 to treat IBS-C by an additional eleven years and significantly strengthens the opportunity
to build long-term value for our shareholders,&rdquo; said Jeffrey Riley, President and Chief Executive Officer of Synthetic Biologics.
&ldquo;We remain focused on the continued clinical advancement of SYN-010 and are encouraged that we are making excellent progress
in providing patients with a novel, potentially best-in-class therapy that directly targets an underlying cause of the symptoms
associated with IBS-C.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Previously announced results from Phase
2 clinical trials conducted by Synthetic Biologics demonstrated SYN-010 significantly reduced abdominal pain and bloating while
also improving stool frequency and quality of life scores without severe adverse events in IBS-C patients. Following collaborative
discussions with the U.S. Food and Drug Administration (FDA), the Company announced the approval of a Phase 2b/3 adaptive design
pivotal trial intended to further evaluate the efficacy and safety of SYN-010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About SYN-010</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-010 is a proprietary, modified-release
formulation of lovastatin lactone that is intended to reduce methane production by certain microorganisms (<I>M. smithii</I>)
in the gut while minimizing disruption to the microbiome to treat an underlying cause of IBS-C. Methane produced by <I>M. smithii
</I>has been correlated with bloating, pain and constipation associated with IBS-C. SYN-010 is intended to act primarily in the
intestinal lumen while avoiding systemic absorption, thereby targeting a major cause of IBS-C, not just the symptoms. To access
the SYN-010 mechanism of action video on Synthetic Biologics&rsquo; website, please <FONT STYLE="color: Blue"><U>click here</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients.
The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut
microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of <I>C. difficile
</I>infection, pathogenic overgrowth and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to
reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome
with constipation (IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and
treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information,
please visit Synthetic Biologics' website at <FONT STYLE="color: Blue"><U>www.syntheticbiologics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements
can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates&quot; and similar expressions
and include statements regarding the further strengthening of the patent portfolio and the continued clinical advancement of SYN-010.
These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and
are subject to a number of risks and uncertainties that could cause actual results to differ materially from those set forth or
implied by any forward-looking statements.&nbsp;Important factors that could cause actual results to differ materially from current
expectations include, among others, Synthetic Biologics' product candidates demonstrating safety and effectiveness, as well as
results that are consistent with prior results, Synthetic Biologics' ability to initiate clinical trials and if initiated, to complete
them on time and achieve desired results and benefits, Synthetic Biologics' clinical trials continuing enrollment as expected,
Synthetic Biologics' ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing
regulatory requirements, regulatory limitations relating to Synthetic Biologics' ability to promote or commercialize its product
candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing
or sale of Synthetic Biologics' products by competitors that render Synthetic Biologics' products obsolete or non-competitive,
Synthetic Biologics' ability to maintain its license agreements, the continued maintenance and growth of Synthetic Biologics'&nbsp;patent
estate, Synthetic Biologics becoming and remaining profitable, Synthetic Biologics'&nbsp;ability to establish and maintain collaborations,
Synthetic Biologics'&nbsp;ability to obtain or maintain the capital or grants necessary to fund its research and development activities,
a loss of any of Synthetic Biologics'&nbsp;key scientists or management personnel,&nbsp;and other factors described in Synthetic
Biologics' Annual Report on Form 10-K for the year ended December 31, 2016 and its other filings with the SEC, including subsequent
periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and Synthetic
Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information,
future events, or otherwise, excepted as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240)
660-2000, <FONT STYLE="color: Blue"><U>info@syntheticbiologics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Feinstein Kean Healthcare (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <FONT STYLE="color: Blue"><U>gregory.kelley@fkhealth.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 1T# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
